Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

BioNTech

Biotech & Life Sciences · Mainz, Germany · Founded 2008 · IPO 2019 Decacorn

Develops personalized immunotherapies with a focus on cancer medicine

Valuation
$9.04B
Market cap · May/2026
Revenue
$3.16B
Latest reported FY

Investors

17 investors on BioNTech's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 3 investors entered at this stage
Santo Holding
MIG Capital
ATHOS Venture
Series A 6 investors entered at this stage
Janus Henderson Investors
Janus Henderson
Eli Lilly
Invus
Redmile Group
Fidelity Investments
Series B+ 8 investors entered at this stage
Sanofi
Genentech
Temasek
Jebsen Capital
Mirae Asset Venture Investment
Bayer
Johannes Gutenberg University Mainz
Platinum Asset Management

Global footprint

Where BioNTech has talent and traffic

AI talent share
1.5% of workforce is AI talent
(76 of 5,107 staff)
Core AI240.47%
Other AI521.02%
Non-AI workforce5,03198.51%
Workforce by country
39 countries with
team presence
🇩🇪 Germany75.4%
🇺🇸 United States16.5%
🇬🇧 United Kingdom2.4%
🇸🇬 Singapore1.4%
🏳️ Rwanda0.7%
Top 5 of 39 shown
Web traffic by country
130K monthly visits
across markets
🇩🇪 Germany32.4%
🇺🇸 United States18.2%
🇬🇧 United Kingdom10%
🇮🇳 India7.8%
🇦🇺 Australia3.8%
Top 5 markets shown

Patent intelligence

$780M patent portfolio · 457 active families

Estimated portfolio value
$780M
8.6% of market cap · 2.8× the top peer argenx ($275M)
457 active patent families
Where BioNTech innovates Molecular biologyPharmaceutical drugCancer researchTGE VACCINECarcinosis

Where BioNTech concentrates vs peers

Each axis is a top-10 topic across BioNTech and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

BioNTech's 13 investments and acquisitions.

Every disclosed deal where BioNTech appeared as a backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

13 deals across BioNTech's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where BioNTech deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        BioNTech's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        13 of 13 deals

        Market sentiment

        What the market is saying about BioNTech

        An AI-synthesized read of the highest-engagement posts about BioNTech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BioNTech on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.